Cargando…
A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis
Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved. UDCA treatment has an uncertain impact on disease outcomes and has been reported in hig...
Autores principales: | Black, Dennis D., Mack, Cara, Kerkar, Nanda, Miloh, Tamir, Sundaram, Shikha S., Anand, Ravinder, Gupta, Ashutosh, Alonso, Estella, Arnon, Ronen, Bulut, Pinar, Karpen, Saul, Lin, Chuan‐Hao, Rosenthal, Philip, Ryan, Matthew, Squires, Robert H., Valentino, Pamela, Elsea, Sarah H., Shneider, Benjamin L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824074/ https://www.ncbi.nlm.nih.gov/pubmed/31701072 http://dx.doi.org/10.1002/hep4.1421 |
Ejemplares similares
-
Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
por: Buness, Cynthia, et al.
Publicado: (2016) -
Microbiome Responses to Vancomycin Treatment in a Child With Primary Sclerosing Cholangitis and Ulcerative Colitis
por: Britto, Savini Lanka, et al.
Publicado: (2021) -
Reinstitution of pegvaliase therapy during lactation
por: Rohr, Frances, et al.
Publicado: (2022) -
Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid
por: Hochberg, Jessica T., et al.
Publicado: (2023) -
Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)